Role of STING protein in breast cancer: mechanisms and therapeutic implications

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Breast cancer remains a leading cause of cancer death, with metastasis and recurrence posing significant challenges despite therapeutic advances.
• Immunotherapy, including monoclonal antibodies and immune checkpoint inhibitors, has improved survival rates in HER2+ breast cancer and triple-negative breast cancer (TNBC).
• Resistance to cancer immunotherapy and tumor remission are major clinical hurdles.

Purpose of the Study:

• To review the latest findings on the role of the cGAS-STING pathway in breast cancer.
• To discuss recent advances in understanding cGAS-STING pathway activation for therapeutic strategies.
• To highlight the potential of cGAS-STING pathway induction in overcoming treatment resistance.

Main Methods:

• Literature review of recent studies on cGAS-STING pathway and breast cancer.
• Analysis of the role of type I interferon (IFN) signaling in anti-cancer immunity.
• Exploration of therapeutic implications of cGAS-STING pathway activation.

Main Results:

• The cGAS-STING pathway is crucial for anti-cancer immunity, with type I IFN acting as a key mediator between innate and adaptive immunity.
• Type I IFN enhances dendritic cell activity, promotes CD8+ T cell function, and protects effector cells from apoptosis.
• Induction of the cGAS-STING pathway shows promising therapeutic effects, especially in triple-negative breast cancers.

Conclusions:

• The cGAS-STING pathway represents a promising therapeutic target for breast cancer treatment.
• Activating this pathway may help overcome immunotherapy resistance and improve outcomes for TNBC patients.
• Further research into cGAS-STING pathway modulation holds significant potential for advancing breast cancer therapy.